TriSalus Life Sciences announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code, C8004, for the TriNav Infusion System, effective April 1, 2025. This new code provides reimbursement clarity for simulation angiograms, also known as mapping procedures, conducted prior to transarterial radioembolization (TARE).
The introduction of C8004 validates TriNav’s growing role in pre-treatment mapping for Transarterial Radioembolization, reinforcing its value in optimizing Y90 dose delivery. This means Interventional Radiologists and Medicare patients will have access to Pressure-Enabled Drug Delivery (PEDD) for radioembolization procedures with full reimbursement for both mapping and treatment.
TriSalus's initial analysis indicates that the reimbursement level under C8004, combined with standard Medicare payment adjustments, will support continued adoption of TriNav for both mapping and treatment. Using the same catheter for both mapping and treatment helps enhance the accuracy of Y90 dose delivery, potentially improving personalized dosimetry.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.